December 18, 2025 · Form 4 insider transaction
Westlake BioPartners Opportunity Fund I, L.P. bought 133,333 shares of Kyverna Therapeutics, Inc. at $7.50 per share, a transaction worth $1000.0K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4.